LCD Reference Article Response To Comments Article

Response to Comments: Colon Capsule Endoscopy (CCE) (DL38837)

A58624

Expand All | Collapse All

Contractor Information

Contractor Name	Contract Type	Contract Number	Jurisdiction	States
Wisconsin Physicians Service Insurance Corporation	MAC - Part A	05101 - MAC A	J - 05	Iowa
Wisconsin Physicians Service Insurance Corporation	MAC - Part B	05102 - MAC B	J - 05	Iowa
Wisconsin Physicians Service Insurance Corporation	MAC - Part A	05201 - MAC A	J - 05	Kansas
Wisconsin Physicians Service Insurance Corporation	MAC - Part B	05202 - MAC B	J - 05	Kansas
Wisconsin Physicians Service Insurance Corporation	MAC - Part A	05301 - MAC A	J - 05	Missouri - Entire State
Wisconsin Physicians Service Insurance Corporation	MAC - Part B	05302 - MAC B	J - 05	Missouri - Entire State
Wisconsin Physicians Service Insurance Corporation	MAC - Part A	05401 - MAC A	J - 05	Nebraska
Wisconsin Physicians Service Insurance Corporation	MAC - Part B	05402 - MAC B	J - 05	Nebraska
Wisconsin Physicians Service Insurance Corporation	MAC - Part A	05901 - MAC A	J - 05	Alabama Alaska Arizona Arkansas California - Entire State Colorado Connecticut Delaware Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Mississippi Missouri - Entire State Montana Nebraska Nevada New Hampshire New Jersey New Mexico North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington West Virginia Wisconsin Wyoming
Wisconsin Physicians Service Insurance Corporation	MAC - Part A	08101 - MAC A	J - 08	Indiana
Wisconsin Physicians Service Insurance Corporation	MAC - Part B	08102 - MAC B	J - 08	Indiana
Wisconsin Physicians Service Insurance Corporation	MAC - Part A	08201 - MAC A	J - 08	Michigan
Wisconsin Physicians Service Insurance Corporation	MAC - Part B	08202 - MAC B	J - 08	Michigan

Article Information

General Information

Article ID
A58624

Article Title
Response to Comments: Colon Capsule Endoscopy (CCE) (DL38837)

Article Type
Response to Comments

Original Effective Date
03/28/2021

Retirement Date
N/A

AMA CPT / ADA CDT / AHA NUBC Copyright Statement

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

Copyright © 2024, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the American Hospital Association (AHA) copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB‐04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312‐893‐6816.

Making copies or utilizing the content of the UB‐04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB‐04 Manual and/or codes and descriptions; and/or making any commercial use of UB‐04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. The American Hospital Association (the "AHA") has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates.

Article Guidance

Article Text

The following are the comment summaries and contractor responses for WPS Proposed Local Coverage Determination (LCD) DL38837 Colon Capsule Endoscopy (CCE), which was posted for comment on 10/01/2020, and presented at the Open Meeting on 10/14/2020. All comments were reviewed and incorporated into the final LCD where applicable. Thank you for the comments.

Response To Comments

Number	Comment	Response
1	The commenter writes in support of the proposed colon capsule endoscopy (CCE) coverage. The commenter is in agreement with the proposed indications for CCE utilization based on the present FDA approved indications. The commenter provided several points in support of the indications and feels the proposed coverage for CCE will enhance the care for the small subset of patients who have been referred for colonoscopy but were unable to have a technically complete study or were felt to be too high risk medically to undergo the procedure. The commenter is in full support in the approval of this coverage.	Thank you for your comment; we appreciate your support in the proposed coverage for CCE.
2	The commenter requests consideration to slightly change the language in the History/Background and/or General Information section to read: "As the capsule travels through the digestive tract, the camera system takes pictures. The images are then transmitted to a computer with special software where the images are strung together to create a video. The provider reviews the video to look for any abnormalities within the gastrointestinal tract." The commenter also requests the following language for consideration to the Coverage Indications, Limitations and/or Medical Necessity section: "CCE devices are covered when the device has received Food and Drug Administration (FDA) market clearance for that device's FDA-approved indication or is used in a CMS approved clinical trial that meets all of the conditions specified." The commenter suggests the following change to the limitations number 2. Patients with a cardiac pacemaker or another implanted-electro-medical device. The commenter indicates the current issue with patients who have an electro-medical device is because the currently approved colon capsule endoscopy device emits a radiofrequency signal. Devices in development do not and therefore, patients with an implanted electro-medical device would be able to have a procedure if it were performed with such a device when it is cleared for marketing by the U.S. Food and Drug Administration. The commenter suggests that the language be updated to read: " 2. Patients with a cardiac pacemaker of another implanted electro-medical device if the CCE device is contraindicated due to emission of a radiofrequency signal or other interfering signal."	Thank you for your comments. We have revised the History/background and/or General Information section as suggested and have reworded limitation #2.
3	The commenter is pleased that the proposed LCD is largely in alignment with the FDA approved indications for PillCam COLON 2. The commenter has some concerns with the Covered Indications in the proposed LCD. The commenter appreciates the inclusion of medical necessity criteria for CCE as a primary procedure for patients with major risks for Optical Colonoscopy (OC) or moderate sedation as indicated from an evaluation of the patient by the physician. The commenter strongly believes these decisions are best left to the patient's physician to determine based on the patient's clinical presentation or history. Any additional requirements to this criterion could create unnecessary barriers to CCE as a diagnostic option; thus, potentially negatively impacting the continuum of care or early diagnosis and patient prognosis. The criteria for CCE as a primary procedure for patients with major risks for OC or moderate sedation includes the requirement of either Fecal Occult Blood Test (FOBT) positive (guaiac or immunochemical) or Multitarget Stool DNA (sDNA) Test positive. The FDA cleared indication for PillCam Colon does not define "evidence of lower GI bleeding." The commenter agrees that FOBT and sDNA tests would help identify those patients with occult GI bleeding. However, hemodynamically stable patients with overt GI bleeding, such as those with scant intermittent melena or hematochezia, may be candidates for PillCam and may not necessarily undergo a stool test given presumed positivity of the test. Therefore, requiring a positive stool test in these patients seems unnecessary. Therefore, the commenter proposes the addition of a third bullet point, "OR other evidence of lower GI bleeding." The commenter requests additional ICD-10-CM codes K92.1 (melena) and K92.2 (gastrointestinal hemorrhage, unspecified) be added to the Local Coverage Article: Billing and Coding: Colon Capsule Endoscopy. The commenter indicates under the proposed LCD, CCE is covered as a secondary procedure for the surveillance of colon polyp(s) if the OC was incomplete OR when an incomplete diagnostic OC was performed for either: Fecal Occult Blood Test (FOBT) positive (guaiac or immunochemical) OR Multitarget Stool DNA (sDNA) Test positive. This proposed language would allow CCE as a secondary procedure after incomplete OC only in the setting of previously diagnosed pathology, whether it be polyps or positive stool test. However, the FDA cleared indication for CCE allows the device to be used for the detection of colon polyps after incomplete OC with adequate prep, regardless of history of colon polyps or positive stool tests. The commenter is concerned that the proposed use of CCE after incomplete colonoscopy is limited to patients with a history of polyps or positive stool tests. When a colonoscopy is incomplete, the proximal colon may not be completely evaluated, potentially missing relevant polyps or other colonic findings. Under the proposed policy, a patient is required to have a prior polyp identified or a positive stool test before CCE is medically necessary. This restriction limits the use of CCE in an important subset of patients that may have a polyp or other colonic findings in the proximal colon, however it was never detected because the proximal colon was not accessible by the colonoscope. The commenter states the importance of visualizing the proximal colon to the cecum is well supported in the literature. Intubation of the cecum is of critical importance because interval cancers are often located in the proximal colon and the development of interval cancers is more frequent after an incomplete exam. The commenter suggests the following alternative phrasing for secondary procedures: "Secondary procedure for the detection or surveillance of colon polyps in patients after an incomplete optical colonoscopy with adequate preparation, and a complete evaluation of the colon was not technically possible."	Thank you for your comments. We have revised the indications for primary and secondary procedures to include "other evidence of lower GI bleeding in hemodynamically stable patients" as a third bullet. We have added diagnosis codes K92.1 (melena) and K92.2 (gastrointestinal hemorrhage, unspecified) as codes that support medical necessity. We have revised the secondary procedure wording to state "for the detection or surveillance of colon polyp(s) if the diagnostic OC was incomplete OR…."
4	The commenter is in support of the decision for local coverage decision for PillCam COLON. The commenter indicates PillCam COLON as a noninvasive means to evaluate the colon of individuals who cannot undergo colonoscopy due to other medical conditions or fear of the procedure is an instrumental tool that can help patients.	Thank you for your comment; we appreciate your support in the proposed coverage for CCE.
5	The commenter is pleased the policy is being updated but indicates the covered indications as a primary procedure lists two indications that may invite a deviation from the standard of care. The current standard of care is to proceed with colonoscopy in the event of positive FOBT or stool DNA. The term "major risk for colonoscopy or moderate sedation" is open to broad interpretation. The commenter suggests using ASA class 3 or greater and after the clinical assessment of the endoscopist performing the procedure. The commenter recommends removing item 2 under limitations regarding pacemakers. The commenter indicates it is well established now and nearly 20 years after FDA approval and in after extensive clinical use that CE can be safely done in patients with implantable devices. While the package insert lists these devices as a contraindication, there is extensive clinical use demonstrating safety and efficacy. The commenter suggests removing limitation 4 regarding contraindication or allergy to any medication or preparation agent used before or during the procedure. The commenter indicates it is not the purview or responsibility for LCDs to advise on the prep. The way it is written, any allergy to any prep solution would be a contraindication even if it is not used. The commenter recommends adding that MRI should not be done in patients undergoing CCE and a flat plate of the abdomen ordered if there is concern for capsule retention after study completion. Regarding the clinical literature, the commenter indicates in reference to Rex et al. study; 26% false negative findings for SSA polyps is unacceptably high. This was a sentinel study and it should be recognized that CCE is inferior to well performed colonoscopy in detecting these lesions. The commenter recommends dropping the Kobaek-Larsen 2018 study as a reference as there are significant methodologic flaws in the study the least of which was the study design used colonoscopy as the standard against which to measure CCE and they concluded that CCE was superior. Statistical fundamentals apply; the best that one can conclude in the study design is non-inferiority. While peer reviewed, it was not published in a top tier journal. In the systematic reviews, the declaration by 2018 Emergency Care Research Institute as "somewhat favorable" is a weak endorsement. In the analysis of evidence, the commenter disagrees with the word "suitable" in and recommends rephrasing as "…CCE is an alternative to OC…" and "In addition, CCE is a secondary procedure…"	Thank you for your comments. No changes will be made to the "major risk for colonoscopy or moderate sedation" at this time. We have revised the wording to limitation #2 to state "patients with a cardiac pacemaker or another implanted electro-medical device that emits a radiofrequency or other interfering signal." No changes will be made with regards to limitation #4 at this time. We do not feel a need to state "MRI should not be done in patients undergoing CCE and a flat plate of the abdomen ordered if there is concern for capsule retention after study completion" at this time. With regards to the Rex et al. and Kobaek-Larsen clinical literature, no changes will be made as we do not recognize them as superior. With regards to the analysis of evidence section and the word "suitable", the wording had been revised as suggested.

Coding Information

CPT/HCPCS Codes

Expand All | Collapse All

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

ICD-10-CM Codes that Support Medical Necessity

Expand All | Collapse All

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

ICD-10-CM Codes that DO NOT Support Medical Necessity

Expand All | Collapse All

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

ICD-10-PCS Codes

Expand All | Collapse All

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

Additional ICD-10 Information

Bill Type Codes

Code	Description

Revenue Codes

Code	Description

Coding Table Information

Excluded CPT/HCPCS Codes - Table Format

Code	Descriptor Generic Name	Descriptor Brand Name	Exclusion Effective Date	Exclusion End Date	Reason for Exclusion
			N/A	N/A

Non-Excluded CPT/HCPCS Ended Codes - Table Format

Code	Descriptor Generic Name	Descriptor Brand Name	Exclusion Effective Date	Exclusion End Date	Reason for Exclusion

Revision History Information

N/A

Associated Documents

Related Local Coverage Documents
Articles
A58471 - Billing and Coding: Colon Capsule Endoscopy (CCE)
LCDs
L38837 - Colon Capsule Endoscopy (CCE)

Updated On	Effective Dates	Status
02/02/2021	03/28/2021 - N/A	Currently in Effect	You are here

Keywords

N/A

Read the Article Disclaimer

Please review and accept the agreements in order to view Medicare Coverage documents, which may include licensed information and codes.

LICENSE FOR USE OF PHYSICIANS' CURRENT PROCEDURAL TERMINOLOGY, FOURTH EDITION ("CPT")

End User Point and Click Amendment:

CPT codes, descriptions and other data only are copyright 2023 American Medical Association. All Rights Reserved (or such other date of publication of CPT). CPT is a trademark of the American Medical Association (AMA).

You, your employees and agents are authorized to use CPT only as agreed upon with the AMA internally within your organization within the United States for the sole use by yourself, employees and agents. Use is limited to use in Medicare, Medicaid or other programs administered by the Centers for Medicare and Medicaid Services (CMS). You agree to take all necessary steps to insure that your employees and agents abide by the terms of this agreement.

Any use not authorized herein is prohibited, including by way of illustration and not by way of limitation, making copies of CPT for resale and/or license, transferring copies of CPT to any party not bound by this agreement, creating any modified or derivative work of CPT, or making any commercial use of CPT. License to use CPT for any use not authorized herein must be obtained through the AMA, CPT Intellectual Property Services, AMA Plaza 330 N. Wabash Ave., Suite 39300, Chicago, IL 60611-5885. Applications are available at the AMA Web site, http://www.ama-assn.org/go/cpt.

Applicable FARS\DFARS Restrictions Apply to Government Use.

AMA Disclaimer of Warranties and Liabilities.

CPT is provided "as is" without warranty of any kind, either expressed or implied, including but not limited to, the implied warranties of merchantability and fitness for a particular purpose. No fee schedules, basic unit, relative values or related listings are included in CPT. The AMA does not directly or indirectly practice medicine or dispense medical services. The responsibility for the content of this file/product is with CMS and no endorsement by the AMA is intended or implied. The AMA disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this file/product. This Agreement will terminate upon notice if you violate its terms. The AMA is a third party beneficiary to this Agreement.

CMS Disclaimer

The scope of this license is determined by the AMA, the copyright holder. Any questions pertaining to the license or use of the CPT should be addressed to the AMA. End Users do not act for or on behalf of the CMS. CMS DISCLAIMS RESPONSIBILITY FOR ANY LIABILITY ATTRIBUTABLE TO END USER USE OF THE CPT. CMS WILL NOT BE LIABLE FOR ANY CLAIMS ATTRIBUTABLE TO ANY ERRORS, OMISSIONS, OR OTHER INACCURACIES IN THE INFORMATION OR MATERIAL CONTAINED ON THIS PAGE. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

Should the foregoing terms and conditions be acceptable to you, please indicate your agreement and acceptance by clicking below on the button labeled "I Accept".

LICENSE FOR USE OF CURRENT DENTAL TERMINOLOGY (CDT^TM)

The license granted herein is expressly conditioned upon your acceptance of all terms and conditions contained in this agreement. By clicking below on the button labeled "I accept", you hereby acknowledge that you have read, understood and agreed to all terms and conditions set forth in this agreement.

If you do not agree with all terms and conditions set forth herein, click below on the button labeled "I do not accept" and exit from this computer screen.

If you are acting on behalf of an organization, you represent that you are authorized to act on behalf of such organization and that your acceptance of the terms of this agreement creates a legally enforceable obligation of the organization. As used herein, "you" and "your" refer to you and any organization on behalf of which you are acting.

Subject to the terms and conditions contained in this Agreement, you, your employees and agents are authorized to use CDT only as contained in the following authorized materials and solely for internal use by yourself, employees and agents within your organization within the United States and its territories. Use of CDT is limited to use in programs administered by Centers for Medicare & Medicaid Services (CMS). You agree to take all necessary steps to ensure that your employees and agents abide by the terms of this agreement. You acknowledge that the ADA holds all copyright, trademark and other rights in CDT. You shall not remove, alter, or obscure any ADA copyright notices or other proprietary rights notices included in the materials.
Any use not authorized herein is prohibited, including by way of illustration and not by way of limitation, making copies of CDT for resale and/or license, transferring copies of CDT to any party not bound by this agreement, creating any modified or derivative work of CDT, or making any commercial use of CDT. License to use CDT for any use not authorized herein must be obtained through the American Dental Association, 211 East Chicago Avenue, Chicago, IL 60611. Applications are available at the American Dental Association web site, http://www.ADA.org.
Applicable Federal Acquisition Regulation Clauses (FARS)/Department of Defense Federal Acquisition Regulation supplement (DFARS) Restrictions Apply to Government Use. U.S. Government Rights Provisions.
Organizations who contract with CMS acknowledge that they may have a commercial CDT license with the ADA, and that use of CDT codes as permitted herein for the administration of CMS programs does not extend to any other programs or services the organization may administer and royalties dues for the use of the CDT codes are governed by their commercial license.
ADA DISCLAIMER OF WARRANTIES AND LIABILITIES. CDT is provided "as is" without warranty of any kind, either expressed or implied, including but not limited to, the implied warranties of merchantability and fitness for a particular purpose. No fee schedules, basic unit, relative values or related listings are included in CDT. The ADA does not directly or indirectly practice medicine or dispense dental services. The sole responsibility for software, including any CDT and other content contained therein, is with CMS; and no endorsement by the ADA is intended or implied. The ADA expressly disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this file/product. This Agreement will terminate upon notice to you if you violate the terms of this Agreement.

The ADA is a third party beneficiary to this Agreement.
CMS DISCLAIMER. The scope of this license is determined by the ADA, the copyright holder. Any questions pertaining to the license or use of the CDT should be addressed to the ADA. End Users do not act for or on behalf of the CMS. CMS disclaims responsibility for any liability attributable to end user use of the CDT. CMS will not be liable for any claims attributable to any errors, omissions, or other inaccuracies in the information or material covered by this license. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

The license granted herein is expressly conditioned upon your acceptance of all terms and conditions contained in this agreement. If the foregoing terms and conditions are acceptable to you, please indicate your agreement by clicking below on the button labeled "I Accept". If you do not agree to the terms and conditions, you may not access or use software. Instead you must click below on the button labeled "I Do Not Accept" and exit from this computer screen.

License For Use of National Uniform Billing Committee (NUBC) UB-04

These materials contain NUBC Official UB-04 Specifications (UB-04 Data), which is copyrighted by the American Hospital Association (AHA).

THE LICENSE GRANTED HEREIN IS EXPRESSLY CONDITIONED UPON YOUR ACCEPTANCE OF ALL TERMS AND CONDITIONS CONTAINED IN THIS AGREEMENT. BY CLICKING BELOW ON THE BUTTON LABELED "I ACCEPT", YOU HEREBY ACKNOWLEDGE THAT YOU HAVE READ, UNDERSTOOD AND AGREED TO ALL TERMS AND CONDITIONS SET FORTH IN THIS AGREEMENT.

IF YOU DO NOT AGREE WITH ALL TERMS AND CONDITIONS SET FORTH HEREIN, CLICK BELOW ON THE BUTTON LABELED "I DO NOT ACCEPT" AND EXIT FROM THIS COMPUTER SCREEN. IF YOU ARE ACTING ON BEHALF OF AN ORGANIZATION, YOU REPRESENT THAT YOU ARE AUTHORIZED TO ACT ON BEHALF OF SUCH ORGANIZATION AND THAT YOUR ACCEPTANCE OF THE TERMS OF THIS AGREEMENT CREATES A LEGALLY ENFORCEABLE OBLIGATION OF THE ORGANIZATION. AS USED HEREIN, "YOU" AND "YOUR" REFER TO YOU AND ANY ORGANIZATION ON BEHALF OF WHICH YOU ARE ACTING.

Subject to the terms and conditions contained in this Agreement, you, your employees, and agents are authorized to use UB-04 Data only as contained in the following authorized materials and solely for internal use by yourself, employees and agents within your organization within the United States and its territories. Use of UB-04 Data is limited to use in programs administered by Centers for Medicare & Medicaid Services (CMS). You agree to take all necessary steps to ensure that your employees and agents abide by the terms of this Agreement. You acknowledge that the AHA holds all copyright, trademark, and other rights in UB-04 Data. You shall not remove, alter, or obscure any AHA copyright notices or other proprietary rights notices included in the materials.
Any use not authorized herein is prohibited, including, by way of illustration and not by way of limitation, making copies of UB-04 Data for resale and/or license, transferring copies of UB-04 Data to any party not bound by this agreement, creating any modified or derivative work of UB-04 Data, or making any commercial use of UB-04 Data. License to use UB-04 Data for any use not authorized herein must be obtained through the American Hospital Association, 155 N. Wacker Drive, Suite 400, Chicago, Illinois, 60606. Applications are available at the NUBC website, http://www.nubc.org/.
The UB-04 Data included in this product is commercial technical data and/or computer databases and/or commercial computer software and/or commercial computer software documentation, as applicable, which was developed exclusively at private expense by the American Hospital Association, 155 N. Wacker Drive, Suite 400, Chicago, Illinois 60606. U.S. Government rights to use, modify, reproduce, release, perform, display, or disclose these technical data and/or computer data bases and/or computer software and/or computer software documentation are subject to the limited rights restrictions of DFARS 252.227-7015(b)(2) (November 1995) and/or subject to the restrictions of DFARS 227.7202-1(a) (June 1995) and DFARS 227.7202-3(a) (June 1995), as applicable for U.S. Department of Defense procurements and the limited rights restrictions of FAR 52.227-14 (December 2007) and FAR 52.227-19 (December 2007), as applicable, and any applicable agency FAR Supplements, for non-Department of Defense Federal procurements.
AHA DISCLAIMER OF WARRANTIES AND LIABILITIES. UB-04 Data is provided "as is" without warranty of any kind, either expressed or implied, including but not limited to, the implied warranties of merchantability and fitness for a particular purpose. The sole responsibility for the software, including any UB-04 Data and other content contained therein, is with the Medicare/Medicaid Contractor or the CMS; and no endorsement by the AHA is intended or implied. The AHA expressly disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this file/product. This Agreement will terminate upon notice to you if you violate the terms of this Agreement. The AHA is a third-party beneficiary to this Agreement.
CMS DISCLAIMER. The scope of this license is determined by the AHA, the copyright holder. Any questions pertaining to the license or use of the UB-04 Data should be addressed to the AHA. End users do not act for or on behalf of the CMS. CMS DISCLAIMS RESPONSIBILITY FOR ANY LIABILITY ATTRIBUTABLE TO END USER USE OF THE UB-04 DATA. CMS WILL NOT BE LIABLE FOR ANY CLAIMS ATTRIBUTABLE TO ANY ERRORS, OMISSIONS, OR OTHER INACCURACIES IN THE INFORMATION OR MATERIAL COVERED BY THIS LICENSE. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

Submit Feedback/Ask a Question

Response to Comments: Colon Capsule Endoscopy (CCE) (DL38837)

Document Note

Note History

Contractor Information

Article Information

General Information

CMS National Coverage Policy

Article Guidance

Response To Comments

Coding Information

Bill Type Codes

Revenue Codes

CPT/HCPCS Codes

Group 1

CPT/HCPCS Modifiers

Group 1

ICD-10-CM Codes that Support Medical Necessity

Group 1

ICD-10-CM Codes that DO NOT Support Medical Necessity

Group 1

ICD-10-PCS Codes

Group 1

Additional ICD-10 Information

Bill Type Codes

Revenue Codes

Other Coding Information

Group 1

Coding Table Information

Revision History Information

Associated Documents

Keywords

Page Help for Article - Response to Comments: Colon Capsule Endoscopy (CCE) (DL38837) (A58624)

Introduction

Finding a specific code

More information

Printing a Document to PDF

Get email updates

CMS & HHS WEBSITES

HELPFUL LINKS

RSS FEEDS